Neutral endopeptidase inhibition potentiates the renal actions of atrial natriuretic factor. Atrial natriuretic factor (ANF) is degraded by neutral endopeptidase. We hypothesized that neutral endopeptidase inhibition (NEP-I) increases sodium excretion and that this effect would be potentiated in the presence of an isolated increase in intrarenal ANF. In seven anesthetized dogs, ANF was infused into one renal artery to produce pathophysiologic concentrations in the supplemented kidney while the control kidney received physiologic circulating concentrations of ANF. In the control kidney, NEP-I (SQ 28,603) produced significant increases in urine flow, absolute sodium excretion and fractional sodium excretion while glomerular filtration rate (GFR) remained constant. These renal actions of NEP-I were associated with marked increases in urinary excretion of ANF and cyclic GMP consistent with decreased renal degradation and increased biologic activity of ANF. All of these effects were significantly greater in the supplemented kidney. The present study suggests that NEP-I produces natriuresis which appears to be independent of changes in GFR. In addition, while NEP-I mimics the renal action of pathophysiologic levels of ANF, NEP-I also potentiates the natriuretic effects of pathophysiologic concentrations of ANF as observed in congestive heart failure or hypertension.
of pharmacologic concentrations of synthetic ANF [10] [11] [12] [13] [14] [15] [16] [17] [18] . NEP-! consistently enhanced renal sodium and water excretion, often in association with further increases in circulating levels of ANF. These studies attributed the renal action of NEP-I to the increases in circulating ANF produced by inhibition of intra-and extrarenal ANF degradation [13, 14, 16, 17] . These studies, however, failed to determine whether the renal action was mediated by an increase in glomerular filtration rate (GFR) and/or a decrease in tubular reabsorption. Moreover, these studies did not address the ability of NEP-I to potentiate the local action of ANF within the nephron independent of changes in circulating ANF.
The current study was designed to determine the action of NEP-I (SQ 28,603) upon bilateral renal hemodynamic and excretory function in normal anesthetized dogs in which one kidney was exposed to physiologic concentrations of ANF and the contralateral kidney was infused with pathophysiologic concentrations of ANF. This design tested the hypothesis that NEP-I is natriuretic and that pathophysiologic concentrations of ANF potentiate the renal tubular actions of NEP-I, thus enhancing the natriuresis following NEP-I.
Methods

Surgical preparation
Experiments were conducted on seven mongrel dogs weighing 17 to 26 kg. All dogs were given lithium carbonate 300 mg orally and fasted 16 to 20 hours prior to the experiment. Dogs were permitted to drink water ad libitum until the time of the experiments. Anesthesia was accomplished with pentobarbital 30 mg/kg with supplemental 65 mg doses given as needed throughout the experiment. The animals were intubated and mechanically ventilated (Harvard Respirator, Harvard Apparatus, Millis, Massachusetts, USA) with supplemental oxygen at 4 liters per minute. A femoral artery was cannulated for monitoring of arterial pressure and blood sampling. Femoral veins were cannulated for infusion of inulin and injection of the NEP-I and supplemental anesthetic. A balloon-tipped, flowdirected pulmonary artery catheter (Model 93-l2lA, 7 Fr., American Edwards Laboratories, Santa Ana, California, USA) was placed via the right internal jugular vein for measurement of cardiac filling pressures and determination of cardiac output by thermodilution. Pulmonary capillary wedge pressure was All data are expressed as mean SEM, N = 7. Abbreviations are: ANF, atrial natriuretic factor; MAP, mean arterial pressure; RAP, right atrial pressure; LAP, left atrial pressure; CO, cardiac output; SVR, systemic vascular resistance; RU, resistance units (mm Hg/mi/mm); PRA, plasma renin activity; ALDO, plasma aldosterone; P1 ANF, plasma atrial natriuretic factor. a p < 0.05 vs. baseline b P < 0.05 pre-NEP-I vs. post-NEP-I used to estimate left atrial pressure and right atrial pressure was measured directly.
Bilateral flank incisions were performed to gain exposure to both kidneys. Each ureter was cannulated for urine collection and a non-cannulating electromagnetic flow probe (Carolina Medical Electronics, King, North Carolina, USA) was placed around each renal artery for on-line measurement of renal blood flow. Curved 23-gauge needles, attached to polyvinyl tubing, were inserted into each renal artery distal to the flow probe and were kept patent by an infusion of 0.9% saline at 0.5 mllmin.
Experimental protocol A priming dose of inulin was given, and a constant infusion of 1 mllmin was begun in an effort to achieve a steady-state plasma level of approximately 70 mg/dl. Following a 60-minute equilibration period, 30-minute baseline renal clearances were performed for each kidney. During this and subsequent clearance periods, blood was drawn for hormonal analyses and determination of inulin, sodium, and lithium concentrations. Cardiac output, mean arterial pressure, right and left atrial pressure, renal blood flow, and urine flow were also measured during each clearance period. Additional urine samples were collected on ice for measurement of urinary ANF and unnary cyclic guanosine monophosphate (cGMP), the latter a biologic marker for renal ANF activity [19] .
Following baseline measurements, an infusion of synthetic a-human ANF (28 aa, Peninsula laboratories, Inc., Belmont, California, USA) was begun at a rate of 2 ng/kg/min into the right renal artery, while the left kidney received the saline vehicle at the same rate. This rate was selected to produce pathophysiologic levels of ANF in the supplemented kidney (SK) without affecting systemic hemodynamics or renal function in the control kidney (CK). A second 30-minute renal clearance was performed beginning 15 minutes after the ANF infusion was begun in the SK. At the conclusion of this clearance period, the NEP-I (SQ 28,603) was given intravenously over two minutes at a dose of 30 mg/kg. SQ 28, 603 (N-[2-(mercaptomethyl)-l-oxo-3-phenylpropyl]--alanine) is a potent competitive inhibitor of neutral endopeptidase 24.11 with a K1 value of 1 nM. SQ 28, 603 is selective in that it shows only weak activity against two other renal brush border peptidases: angiotensin converting enzyme (I = 32 sM) and aminopeptidase M in which there was no inhibition at concentrations up to I /M (Dalaney NO, unpublished data). A third 30 -minute clearance period was started 15 minutes after the NEP-! was given. Finally, the ANF infusion into the SK was discontinued and a 30-minute recovery clearance was begun 15 minutes later. In all experiments, urinary fluid losses were replaced with intravenous normal saline every 15 minutes.
Extracted arterial plasma levels of ANF and urinary ANF levels were measured by radioimmunoassay to a-hANF as previously described [20] . To calculate the increment in renal ANF concentration in the SK produced by the ANF infusion, the infusion rate was divided by the renal plasma flow. The calculated plasma ANF concentration for the SK was obtained by adding this number to the circulating arterial plasma ANF level. Plasma renin activity was determined by radioimmunoassay using the method of Haber et al [21] . Plasma aldosterone concentration was measured by specific radioimmunoassay [3] . Urinary cOMP was measured by radioimmunoassay using the method of Steiner, Parker and Kipnis [22] . Plasma and urinary sodium concentrations were measured using ion-selective electrodes (Beckman Instruments, Brea, Louisiana, USA), and plasma and urine lithium levels were determined by flameemission spectrophotometry (Model 357, Instrumentation Laboratory, Wilmington, Massachusetts, USA). Glomerular filtration rate (GFR) was determined by inulin clearance. Plasma and urine inulin concentrations were determined by the anthrone method [231. Cardiac output was determined by thermodilution (Cardiac Output model 9510-A computer, American Edwards Laboratories, Irvine, California, USA). Systemic vascular resistance was calculated by dividing cardiac output by the difference between mean arterial and right atrial pressures. Renal filtration fraction was determined by dividing GFR by renal plasma flow after assuming the hematocrit was stable at 45%.
All data are presented as mean standard error. Within group comparisons with baseline and before and after NEP-I were made using analysis of variance for repeated measures and Scheffe's multiple comparisons test. Comparisons between SK and CK were analyzed by one-way analysis of variance followed by paired Student's t-test. Statistical significance was defined as P < 0.05.
Results
The systemic hemodynamic and hormonal responses observed during the experimental protocol are presented in Table   1 , and the renal hemodynamic and excretory responses are presented in Table 2 . During ANF infusion the calculated plasma ANF levels in the SK, in excess of 500 pglml, were in the high pathophysiologic range. The small but significant increase in circulating arterial plasma ANF from 29 12 to 47 11 suggested some spillover into the systemic circulation. In addition, right atrial pressure and cardiac output decreased while mean arterial pressure and systemic vascular resistance increased. Plasma renin activity also decreased significantly during the ANF infusion. The renal responses of the SK to pathophysiologic concentrations of ANF included significant increases in GFR, filtration fraction, urine flow, absolute sodium excretion (UNaV), fractional sodium excretion (FENa), and fractional lithium excretion (FELl). Significant decreases in urine osmolality and fractional excretion of ANF were observed in the SK during ANF infusion. No significant changes in the renal function of the CK were observed during this period.
With intravenous administration of NEP-I, systemic plasma ANF increased from 47 11 to 87 25 pg/mI (P < 0.05) despite no change in left or right atrial pressures and no change in mean arterial pressure. Cardiac output decreased and systemic vascular resistance increased while other systemic hemodynamic and hormonal parameters did not change following NEP-!. NEP-I produced substantial changes in renal function in both kidneys. In the CK, GFR was unchanged, renal blood flow and urine osmolality decreased, and urine flow, UNaV, FENa, filtration fraction and renal vascular resistance increased. Urinary cGMP excretion increased significantly compared with baseline, and marked increases in absolute and fractional excretion of ANF were observed. Of note, except for the increases in ANF excretion and the relatively smaller decrease in urine osmolality, the renal responses in the CK following NEP-I did not differ significantly from those observed in the SK during ANF administration despite markedly different renal plasma concentrations of ANF.
In the SK, receiving pathophysiologic concentrations of ANF, GFR and renal blood flow were unchanged. However, marked increases in urine flow, UNaV and FENa were observed following NEP-I and were significantly greater than those observed in the CK which received physiologic circulating concentrations of ANF (Fig. 1) . These increases in sodium and water excretion in the SK were associated with marked increases in fractional excretion of ANF and urinary cGMP excretion. The increases in urine flow, UNaV, FENa, absolute ANF excretion, and cGMP excretion in the SK were all significantly greater than the corresponding increases observed in the CK following NEP-I administration.
Discussion
This study demonstrates that an inhibitor of neutral endopeptidase (SQ 28,603) produced increases in urine flow and absolute and fractional sodium excretion in normal anesthetized dogs. The natriuresis which occurred following NEP-I administration was accompanied by small but significant increases in plasma ANF. These increases in sodium and water excretion occurred in the absence of any significant increases in either GFR or renal blood flow, indicating that a decrease in tubular sodium reabsorption was probably responsible for the observed natriuresis. Although NEP-! may have also interfered with both the intrarenal and systemic degradation of peptides other than ANF, the potentiated natriuresis associated with increased urinary excretion of cGMP in the presence of pathophysiologic concentrations of ANF suggests that the renal natriuretic action of NEP-I may be due to inhibition of the renal inactivation of ANF.
The effect of NEP-I on urine flow and sodium excretion in the normal animal is not clearly defined. In normal conscious rats, Koepke et al [13] reported no effect of endopeptidase inhibition with thiorphan on sodium excretion, in contrast to two preliminary studies reporting thiorphan-induced natriuresis in normal anesthetized rats [10, 12] . Phosphoramidon, another NEP-I, also induced natriuresis and diuresis in anesthetized rats [24] . The present study demonstrates, for the first time, that NEP-I in the anesthetized dog also produces both natriuresis and diuresis, Although the present study was performed in the presence of anesthesia, a recent study by Northridge et al [14] observed natriuresis following administration of an orallyactive NEP-I (UK 69,578) in normal conscious humans. Moreover, in preliminary studies on conscious mice, Samuels et al [25] observed that NEP-I (UK 79,300) produced diuresis and natriuresis during the first hour after its administration. Thus, the data from the current and other published studies indicate that NEP-I results in natriuresis and diuresis in several normal species. To date, however, these recent studies failed to define whether the natriuretic action was mediated by a renal hemodynamic or tubular action of neutral endopeptidase inhibition.
In the current study, NEP-I in the presence of physiologic concentrations of ANF resulted in significant increases in plasma ANF. The increases in circulating ANF were small and remained within the physiologic range. Previous reports suggest some inconsistency in the ability of NEP-I to increase plasma ANF levels. Samuels et al [25] reported a doubling of plasma ANF following administration of NEP-I (UK 79,300) in normal mice, and Northridge et al [14] reported similar results following NEP-I (UK 69,578) in normal humans. In contrast, Koepke et al [13] and Olins et al [26] found thiorphan increased plasma ANF levels in conscious rats only when pharmacologic concentrations of ANF were administered concomitantly. These discrepancies could be due to differences in the NEP-I used, to species differences, or to more subtle differences in experimental design. In the present study, circulating ANF increased despite significant decreases in left and right atrial pressures suggesting that decreases in ANF degradation, rather than hemodynamically-mediated increases in ANF secretion, were responsible.
The natriuresis observed following NEP-I in the present study occurred without significant increases in GFR or renal blood flow. In previous studies by Ura, Carretero and Erdös [24] , the natriuresis produced by phosphoramidon in normal rats similarly occurred in the absence of any significant changes in GFR or renal blood flow. However, the increase in filtration fraction in the CK and the tendency for an increase in the SK indicate that NEP-I may be influencing glomerular dynamics, either the ultrafiltration coefficient (Kf) or efferent arteriolar resistance. Furthermore, recent studies by Mejia et al [27] demonstrate that small (for example, 5%) changes in GFR, which may escape detection by usual clearance methods, can produce significant increases in sodium excretion independent of changes in tubular reabsorption. Thus, while NEP-I appeared to decrease tubular sodium reabsorption in the present study, we cannot exclude subtle changes in GFR as well, particularly in the presence of physiologic levels of ANF. In this regard, the renal action of NEP-I mimics the renal action of low-dose intrarenal ANF infusion. Importantly, the renal action of NEP-I occurs at a lower renal plasma ANF concentration as compared to exogenous ANF. Such an observation is consistent with potentiation of ANF by NEP-I. Following NEP-I we observed significant increases in FENa in both CK and SK, indicating decreases in tubular reabsorption of filtered sodium. The lack of significant increases in FELl further suggests that the major impact of NEP-I on tubular sodium handling occurred beyond the proximal tubule. Previous studies have demonstrated specific membrane-bound receptors for ANF at the inner-medullary collecting duct (IMCD) [28] [29] [30] . ANF action at the IMCD is linked to generation of cGMP [31] [32] [33] which, in turn, attenuates osmotic water permeability [33] . Moreover, Zeidel et al [34] have demonstrated that ANF modulates apical sodium uptake in IMCD cells via inhibition of amiloride-sensitive sodium channels in association with cGMP generation. In the present study, increases in FENa following NEP-I were associated with increases in urinary cGMP in both CK and SK and decreases in urine osmolality, findings compatible with enhanced ANF action at the IMCD.
Marked increases in total urinary excretion of ANF were observed following NEP-I in this study. This finding likely reflects both modest increases in circulating ANF and decreases in renal ANF degradation. Shima et al [9] have demonstrated that proximal tubule brush borders and glomeruli have the greatest ANF degrading capacity. Therefore, increased urinary ANF recovery may, in part, reflect decreased degradation in the proximal nephron. Of interest, fractional excretion of ANF, a marker for tubular handling of ANF, actually decreased during infusion of ANF in the SK. This finding is consistent with the non-saturable nature of the brush border neutral endopeptidase as demonstrated by Berg et al [35] . However, following NEP-I, fractional excretion of ANF increased in both CK and SK, suggesting that decreases in tubular degradation of ANF contributed to increases in urinary recovery of ANF.
While increased distal nephron delivery of ANF may contribute to the observed natriuresis, alternative mechanisms must be considered. Such alternative mechanisms for natriuresis following NEP-I and/or ANF include increases in ANF binding at the basolateral membrane of IMCD cells, changes in intrarenal physical forces or increases in medullary blood flow which might explain the significant decreases in urine osmolality observed following NEP-I.
The NEP-I used in this study, SQ 28,603, has minimal activity against other proximal tubule brush border enzymes, including angiotensin converting enzyme and aminopeptidase M. However, the activity of the compound against other peptidases outside the brush border are undefined. In addition to ANF, neutral endopeptidase hydrolyzes other peptides in vitro including kinins, angiotensins, enkephalins, neurotensin, substance P, insulin 13-chain and endothelin [4, 36, 37] . In the present study, decreases in degradation of non-ANF peptides, particularly kinins, could have contributed to natriuresis following NEP-I. However, the increased urinary cGMP excretion and potentiated natriuresis in the presence of pathophysiologic levels of ANF suggest that NEP-I enhances sodium excretion predominantly by blocking ANF degradation. Thus, NEP-I may be most effective in states with elevated levels of endogenous ANF, like congestive heart failure and hypertension. On the other hand, observed increases in systemic and renal vascular resistances following NEP-I might be related to decreased neutral peptidase degradation of vasoconstrictor peptides, including angiotensins and endothelin.
In conclusion, this study demonstrates, for the first time, the renal responses to administration of an inhibitor of neutral endopeptidase in the presence of physiologic and pathophysiologic concentrations of ANF in normal anesthetized dogs. The major finding is that NEP-I produces significant increases in sodium and water excretion which are independent of significant changes in GFR or renal blood flow. The enhanced urinary ANF and cGMP excretion, known cGMP-linked action of ANF at the medullary collecting duct, and enhanced diuresis and natriuresis observed in response to administration of pathophysiologic concentrations of ANF all suggest that NEP-I induces sodium excretion primarily by decreasing degradation of ANF. Further, the enhanced natriuresis following NEP-I in the kidney supplemented with pathophysiologic concentrations of ANF support the speculation that NEP-I might potentiate the renal actions of ANF in congestive heart failure or hypertension.
